JP2024530839A - サポニン、オリゴヌクレオチド、およびGalNAcの複合体 - Google Patents

サポニン、オリゴヌクレオチド、およびGalNAcの複合体 Download PDF

Info

Publication number
JP2024530839A
JP2024530839A JP2023578030A JP2023578030A JP2024530839A JP 2024530839 A JP2024530839 A JP 2024530839A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2024530839 A JP2024530839 A JP 2024530839A
Authority
JP
Japan
Prior art keywords
saponin
oligonucleotide
molecule
galnac
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530839A5 (cg-RX-API-DMAC10.html
Inventor
ポステル,ルーベン
ヘアマンス,ガイ
デ ランゲムヒーン,ヘルムス ファン
ビルジャンド,マズダク アサディアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapreme Technologies BV
Original Assignee
Sapreme Technologies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Priority claimed from PCT/NL2021/050549 external-priority patent/WO2022055351A1/en
Application filed by Sapreme Technologies BV filed Critical Sapreme Technologies BV
Publication of JP2024530839A publication Critical patent/JP2024530839A/ja
Publication of JP2024530839A5 publication Critical patent/JP2024530839A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023578030A 2021-06-18 2022-03-08 サポニン、オリゴヌクレオチド、およびGalNAcの複合体 Pending JP2024530839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
NLPCT/NL2021/050384 2021-06-18
NLPCT/NL2021/050549 2021-09-09
PCT/NL2021/050549 WO2022055351A1 (en) 2020-09-10 2021-09-09 Conjugate of saponin, oligonucleotide and galnac
PCT/NL2022/050127 WO2022265493A1 (en) 2021-06-18 2022-03-08 Conjugate of saponin, oligonucleotide and galnac

Publications (2)

Publication Number Publication Date
JP2024530839A true JP2024530839A (ja) 2024-08-26
JP2024530839A5 JP2024530839A5 (cg-RX-API-DMAC10.html) 2025-03-13

Family

ID=80785160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578030A Pending JP2024530839A (ja) 2021-06-18 2022-03-08 サポニン、オリゴヌクレオチド、およびGalNAcの複合体

Country Status (4)

Country Link
US (1) US20240307545A1 (cg-RX-API-DMAC10.html)
EP (2) EP4591938A3 (cg-RX-API-DMAC10.html)
JP (1) JP2024530839A (cg-RX-API-DMAC10.html)
WO (1) WO2022265493A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118356506A (zh) * 2023-01-17 2024-07-19 中国科学院上海药物研究所 去唾液酸糖蛋白受体配体与细胞毒素的偶联物及其应用
GB202300865D0 (en) * 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用
JP2026521777A (ja) * 2023-06-21 2026-07-01 サプリーム テクノロジーズ,ベー.フェー. 中枢神経系障害を処置するための医薬組成物
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509440A (ja) * 1992-07-02 1995-10-19 ケンブリッジ・バイオテック・コーポレイション 変性サポニンによる薬物送達促進方法
US20040242502A1 (en) * 2003-04-08 2004-12-02 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
WO2019011914A1 (en) * 2017-07-11 2019-01-17 Freie Universität Berlin NOVEL USES OF SAPONIN AND METHOD FOR ITS ISOLATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR20160083876A (ko) * 2013-11-14 2016-07-12 로슈 이노베이션 센터 코펜하겐 에이/에스 ApoB 안티센스 접합체 화합물
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
WO2022055351A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509440A (ja) * 1992-07-02 1995-10-19 ケンブリッジ・バイオテック・コーポレイション 変性サポニンによる薬物送達促進方法
US20040242502A1 (en) * 2003-04-08 2004-12-02 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
WO2019011914A1 (en) * 2017-07-11 2019-01-17 Freie Universität Berlin NOVEL USES OF SAPONIN AND METHOD FOR ITS ISOLATION

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOMEDICINES, vol. 5(14):1-25, JPN6025032636, 2017, ISSN: 0005875204 *
BIOMEDICINES, vol. 5(4):Article ID 14, JPN6023048558, 29 March 2017 (2017-03-29), ISSN: 0005875206 *
CURRENT PHARMACEUTICAL DESIGN, vol. 20(42):6584-6643, JPN6023048556, 22 October 2014 (2014-10-22), ISSN: 0005875208 *
MOLECULAR ONCOLOGY, vol. 11(11):1527-1543, JPN6023048557, 15 September 2017 (2017-09-15), ISSN: 0005875207 *
MOLECULAR THERAPY: NUCLEIC ACIDS, vol. 14:67-79, JPN6025032638, 2019, ISSN: 0005875205 *
PHARMACEUTICAL BIOLOGY, vol. 40(4):253-262, JPN6026022425, 2002, ISSN: 0005875203 *

Also Published As

Publication number Publication date
EP4591938A3 (en) 2025-11-05
WO2022265493A1 (en) 2022-12-22
EP4355369C0 (en) 2025-06-18
US20240307545A1 (en) 2024-09-19
EP4355369A1 (en) 2024-04-24
EP4355369B1 (en) 2025-06-18
EP4591938A2 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
EP4171641B1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
EP4355369B1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2021261998A1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
WO2022055352A1 (en) Semicarbazone-based saponin conjugate
EP4210760B1 (en) Conjugate of saponin, oligonucleotide and galnac
JP7862331B2 (ja) GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用
AU2021295358B2 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40124033A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
AU2021339332A1 (en) Conjugate of saponin, oligonucleotide and GalNAc
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
CN117881427A (zh) 皂苷、寡核苷酸和galnac的缀合物
HK40116734A (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
HK40128805A (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
HK40129944A (zh) Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602